[Gefitinib molecular target therapy for Chinese patients with non-small cell lung cancer].
To explore the experience of gefitinib molecular target therapy for Chinese patients with non-small cell lung cancer (NSCLC). The unpublished data of gefitinib for advanced NSCLC in 7 hospitals were collected. The detailed data from Guangdong Provincial People's Hospital were analyzed. A total of 282 patients with advanced NSCLC was treated with gefitinib from July 2001 to December 2003. Response rate was 22.2%-47.7%, disease control rate 62.6%-81.8%. No severe side effects were surveyed. Gefitinib can be used safely and effectively in Chinese patients with advanced NSCLC.